SecBot SecBot
8-K ·Filed Nov 6, 2026

PASG

Passage BIO, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed10d 18h ago SEC0001140361-26-042222
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

All stockholder approvals for the reverse merger have been obtained. The next catalyst is the closing of the merger, which is contingent on remaining conditions. Monitor for the closing announcement and the combined company's cash runway guidance, which the filing suggests may fund operations into 2028.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$3.98
T+0 close · Nov 6, 2026 · via day close
Latest settled
+6.92%
T+5 · $4.25
Vs SPY
+4.32%
α at T+5
Next horizon
T+20
in 20d
  1. T+0 · Nov 6 $3.98entry
  2. T+1 · 8d ago −13.71%α −16.08% · $3.43
  3. T+5 · 4d ago +6.92%α +4.32% · $4.25
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Passage Bio stockholders approved all proposals related to the reverse merger with Remix Therapeutics, including share issuance (representing >20% of outstanding shares and a change of control), a reverse stock split (1:2 to 1:10), name change to Remix Therapeutics, and adoption of new equity incentive and employee stock purchase plans. The merger remains subject to closing conditions, and the combined company expects to be renamed Remix Therapeutics with its lead candidate REM-422.

Key Facts

  • Stockholders approved issuance of Passage Bio common stock to Remix securityholders representing >20% of outstanding shares and resulting in a change of control (Proposal 1: 1,806,227 for, 36,404 against).
  • Stockholders approved a reverse stock split at a ratio from 1-for-2 to 1-for-10, with the final ratio to be mutually agreed by Passage Bio and Remix (Proposal 2: 2,202,453 for, 113,608 against).
  • Stockholders approved amending the charter to change the company name to Remix Therapeutics, Inc. (Proposal 3: 1,809,243 for, 33,290 against).
  • Stockholders approved the Remix Therapeutics 2026 Equity Incentive Plan, reserving 5,772,500 shares (pre-split) plus annual increases (Proposal 5: 1,383,770 for, 458,604 against).
  • Stockholders approved the Remix 2026 Employee Stock Purchase Plan, authorizing 440,000 shares (pre-split) plus annual increases (Proposal 6: 1,490,163 for, 351,988 against).
  • All non-binding advisory proposals on charter provisions (4A through 4H) were approved, with Proposal 4D (supermajority for bylaw amendments) receiving the lowest support at 1,479,152 for vs 363,438 against.
  • As of the record date of September 30, 2026, 3,217,810 shares were outstanding; 2,318,821 shares were represented at the special meeting, constituting a quorum.

Financial Impact

The merger results in a change of control of Passage Bio, with Remix securityholders receiving Passage Bio common stock representing more than 20% of outstanding shares. The exchange ratio is 0.1727 (subject to reverse split adjustment). No deal value or financial terms are disclosed in this filing.

dilutionshares outstanding

Risk Factors

  • The merger remains subject to closing conditions; failure to satisfy conditions could delay or prevent the transaction.
  • The reverse stock split ratio is not yet fixed, creating uncertainty about post-split share count and price.
  • The combined company will have a new name (Remix Therapeutics) and a new lead candidate (REM-422), which is still in early-stage clinical development.
  • The filing notes the combined company will need additional funding, and the CVR (contingent value right) may never pay out.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
67% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-042222
Document: 0001140361-26-042222-index-headers.html0001140361-26-042222
Document: 0001140361-26-042222-index.html0001140361-26-042222
Document: 0001140361-26-042222.txt0001140361-26-042222

Track record

15 reports on PASG

Performance horizon

2 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +22.24% at T+60 after the May 27, 2026 report. 4 of 7 went positive at some point.

Filters
  1. Nov 6, 202610d ago 8-K Neutral 5/10 Viewing Entry $3.98 Now $4.13 +3.90% settles Dec 7
  2. Oct 13, 20265w ago EFFECT Neutral 3/10 Entry $3.64 to $3.78 Now $4.13 +13.46% ▲ +3.85% +7.46% vs SPY
  3. Oct 8, 20265w ago S-4/A Bearish 6/10 Entry $3.69 to $3.98 Now $4.13 −11.92% ▼ −7.72% −13.28% vs SPY
  4. Oct 5, 20266w ago S-4/A Neutral 5/10 Entry $4.08 to $3.41 Now $4.13 +1.23% ▼ −16.47% −13.56% vs SPY
  5. Sep 21, 20268w ago S-4/A Neutral 5/10 Entry $4.95 to $3.60 Now $4.13 −16.57% ▼ −27.27% −26.71% vs SPY
  6. Sep 2, 202610w ago S-4/A / 425 Bearish 8/10 Entry $4.75 to $4.12 Now $4.13 +13.05% ▲ +13.26% +12.08% vs SPY
  7. Sep 2, 202610w ago 8-K Bullish 8/10 Entry $4.75 to $4.12 Now $4.13 −13.05% ▼ −13.26% −12.08% vs SPY
  8. Jun 24, 202620w ago 425 Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
  9. Jun 24, 202620w ago 425 Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
  10. Jun 24, 202620w ago 8-K Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 6, 2026